Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease

Abstract : We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers (France) in patients with amnestic mild cognitive impairment (MCI) receiving Donepezil 10 mg daily or placebo over 12 months, and 6 months open label follow-up. Outcome measures were the rates of global and domain specific cognitive decline as non-primary efficacy endpoint. The intention-to-treat (ITT) sample analyzed comprised 215 cases. Baseline Hp volume was a significant predictor of rates of change in global cognitive function in linear mixed effects models. This effect was independent of treatment. BF volume was not associated with rates of global or domain specific cognitive decline. Rates of delayed free recall decline were higher in MCI cases treated with donepezil compared to placebo. Only Hp, but not BF volume was a useful predictor of cognitive decline in suspected prodromal AD patients. Both Hp and BF volumes were poor predictors of treatment response, questioning previous approaches on predicting treatment response without placebo control. clinicalTrials.gov Identifier NCT00403520.
Liste complète des métadonnées

https://hal.inria.fr/hal-01372417
Contributeur : Olivier Colliot <>
Soumis le : mardi 27 septembre 2016 - 11:25:50
Dernière modification le : jeudi 11 janvier 2018 - 06:28:02

Identifiants

  • HAL Id : hal-01372417, version 1
  • PUBMED : 26876309

Collections

Citation

Stefan J Teipel, Enrica Cavedo, Michel J Grothe, Simone Lista, Samantha Galluzzi, et al.. Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. Neuropharmacology, 2016, 108, pp.128-35. 〈hal-01372417〉

Partager

Métriques

Consultations de la notice

201